ZYCLARA

Peak

imiquimod

NDATOPICALCREAM
Approved
Mar 2010
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
8

Mechanism of Action

Interferon Inducers

Clinical Trials (5)

NCT07251413Phase 1/2Recruiting

Cemiplimab Plus Imiquimod and Laser Therapy As Neoadjuvant Treatment In Cutaneous Basal Cell Carcinoma

Started Oct 2025
18 enrolled
Cutaneous Basal Cell Carcinoma
NCT02301494N/AWithdrawn

Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma

Started Apr 2020
0
Mycosis Fungoides
NCT02130323Phase 2/3Completed

Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix

Started Feb 2015
22 enrolled
Cervical Intraepithelial Neoplasia
NCT03914417Phase 2Completed

Genomic Markers Before and After Treatment of Actinic Keratosis With Imiquimod 3.75% Cream

Started Jan 2013
21 enrolled
Actinic Keratosis
NCT01686152Phase 3Completed

Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis

Started Sep 2012
589 enrolled
Actinic Keratosis

Loss of Exclusivity

LOE Date
Apr 30, 2030
50 months away
Patent Expiry
Apr 30, 2030

Patent Records (5)

Patent #ExpiryTypeUse Code
8598196
Aug 18, 2029
U-1455
10238645
Aug 18, 2029
U-1455
10238644
Dec 11, 2029
U-68
8222270
Dec 11, 2029
U-68
8236816
Dec 11, 2029
U-68